News

Findings from COX 2 studies are released

BMJ 2005; 330 doi: 10.1136/bmj.330.7488.381-a (Published 17 February 2005)
Cite this as: BMJ 2005;330:381.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Scott Gottlieb
  1. New York

    Results from recent studies that raised concerns about the cardiovascular safety of cyclo-oxygenase-2 (COX 2) inhibitors have been made available early, in advance of hearings on the drug class by the US Food and Drug Administration.

    All the studies have been published online in the New England Journal of Medicine (http://nejm.org/), and the journal lifted its normal embargo date for the studies because of what it described as the “possible public health implications.”

    The results come immediately before a three-day hearing looking into the benefits and risks of COX 2 inhibitors …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular